ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
20.95
-0.29 (-1.37%)
Jul 3, 2025, 1:00 PM - Market closed
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 19 analysts that cover ACADIA Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $27.89, which forecasts a 33.13% increase in the stock price over the next year. The lowest target is $20 and the highest is $38.
Price Target: $27.89 (+33.13%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ACADIA Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 4 | 4 | 4 |
| Buy | 6 | 6 | 6 | 4 | 5 | 8 |
| Hold | 7 | 8 | 8 | 8 | 5 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 19 | 16 | 14 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Hold Maintains $19 → $22 | Hold | Maintains | $19 → $22 | +5.01% | Jun 26, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $37 | Buy | Reiterates | $37 | +76.61% | Jun 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +52.74% | Jun 26, 2025 |
| Needham | Needham | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +43.20% | Jun 26, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $26 → $38 | Buy | Maintains | $26 → $38 | +81.38% | Jun 23, 2025 |
Financial Forecast
Revenue This Year
1.09B
from 957.80M
Increased by 13.39%
Revenue Next Year
1.20B
from 1.09B
Increased by 10.59%
EPS This Year
0.56
from 1.36
Decreased by -58.58%
EPS Next Year
0.88
from 0.56
Increased by 56.70%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.1B | 1.4B | 1.6B | ||
| Avg | 1.1B | 1.2B | 1.3B | ||
| Low | 1.0B | 1.1B | 1.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.4% | 28.3% | 32.1% | ||
| Avg | 13.4% | 10.6% | 11.9% | ||
| Low | 7.4% | 1.1% | -3.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.05 | 1.95 | 2.55 | ||
| Avg | 0.56 | 0.88 | 1.47 | ||
| Low | 0.34 | 0.49 | 0.98 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -22.8% | 246.7% | 189.0% | ||
| Avg | -58.6% | 56.7% | 66.6% | ||
| Low | -74.7% | -13.0% | 11.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.